Targeted Systemic Therapy

Phase 3Small molecule

DDavid Palma

Targeted Systemic Therapy is one of 6 small molecule programs targeting Oligometastases. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OligometastasesRecruiting

OligometastasesPhase 3

Recruiting

Competition

Competitive Landscape

5 competitors in Oligometastases

#DrugCompanyPhaseTrials

Immunotherapy

Bristol-Myers Squibb

Phase 3

1 2

Imfinzi

AstraZeneca

Phase 2

1 3

Ceralasertib

AstraZeneca

Phase 2

1 4

Serplulimab

Shanghai Henlius Biotech

Phase 2

1 5

Targeted Systemic Therapy

DDavid Palma

Phase 3

1 6

CAPEOX/XELOX

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Recruiting

Oligometastases

NCT05717166

Q1 2034

Phase 2Recruiting

Esophageal Cancer

NCT07000253

Clinical

Trials by Indication[1]

Oligometastases1 trial

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

Recruiting·DDavid Palma·Phase 3·NCT05717166·180 enrolled

Esophageal Cancer1 trial

Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma: A Randomized Prospective Clinical Study (OMEC-5)

Recruiting·AAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)·Phase 2·NCT07000253·290 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Targeted Systemic Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Targeted Systemic Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Targeted Systemic Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — David Palma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDavid Palma

Targeted Systemic Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q1 2034

Trials by Indication[1]

Oligometastases1 trial

Esophageal Cancer1 trial

References

Drug Info

Quick Facts

Related News